跨不同器官的抗纤维素治疗的现状:一个系统的方法
Isabel Fuster-Martínez1, Sara Calatayud2
1Departamento de Farmacología, Universitat de València, Valencia 46010, Spain; FISABIO (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana), Valencia 46020, Spain.
Pharmacological research
|May 31, 2024
概括
迫切需要有效的抗纤维菌疗法. 本次审查确定了有前途的候选药物,并评估了它们在治疗各种纤维化疾病方面的潜力.
科学领域:
- 病理学 病理学 病理学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 纤维化是一种广泛的病理过程,影响许多器官.
- 目前纤维化治疗的治疗选择有限,这推动了对新治疗方法的研究.
研究的目的:
- 系统地审查目前和最近完成的抗纤维素药物临床试验.
- 分析临床前关于抗纤维菌策略在各种纤维菌疾病中的疗效的数据.
- 确定最有前途的抗纤维素药物选择,并评估它们更广泛应用的潜力.
主要方法:
- 临床试验和临床前研究的系统文献综述.
- 对抗纤维菌药物开发的药理学策略的分析.
- 对不同纤维状症的治疗潜力的评估.
主要成果:
- 有相当数量的临床试验正在研究新型抗纤维素药物.
- 临床前研究提供了关于这些药物的机制和疗效的见解.
- 几种药理学策略显示出治疗纤维化疾病的前景.
结论:
- 抗纤维菌疗法的开发是一个快速发展的领域.
- 识别具有广泛治疗潜力的药物对于管理各种纤维状况至关重要.
- 需要进一步的研究来将有希望的临床前发现转化为有效的临床治疗方法.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K


